Sorry, you need to enable JavaScript to visit this website.

Relapsed: D + PD Study | DARZALEX® IV (daratumumab)

DARZALEX® Clinical Studies:

DARZALEX® in combination with Pomalyst® 
(pomalidomide) + dexamethasone

DARZALEX® was studied in combination with Pomalyst® and dexamethasone (Pd) in 103 patients who had received a prior proteasome inhibitor (PI) and an immunomodulatory agent. These patients had received a median of four prior lines of therapy for their multiple myeloma.

The main goal of the study was to measure overall response rate, which is the percentage of patients who responded to treatment.

Clinical study results: DARZALEX® + Pd vs Pd alone

When these patients were treated with DARZALEX® in combination with Pd, 59% responded

  • This response lasted for a median duration of 13.6 months (range: 0.9+ to 14.6+ months).


Median duration of response

Of patients who responded, response was seen between 0.9 and 2.8 months


Median time it took patients to respond to DARZALEX®


Median time it took patients to respond to DARZALEX®